Vistagen directors to exit board after 2026 meeting

Vistagen Therapeutics, Inc. announced that two members of its Board of Directors, Ms. Margaret FitzPatrick and Dr. Joanne Curley, have chosen not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders.

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. announced that two members of its Board of Directors, Ms. Margaret FitzPatrick and Dr. Joanne Curley, have chosen not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Both directors will continue to serve on the board until their current terms end at the 2026 Annual Meeting. The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol VTGN.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Annual Meeting of Stockholders, Nasdaq Capital Market, Emerging Growth Company

3 terms

Annual Meeting of Stockholders financial

"notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders"

Nasdaq Capital Market financial

"Common Stock, par value $0.001 per share | VTGN | Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Emerging Growth Company regulatory

"Emerging Growth Company o"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board changes did Vistagen Therapeutics (VTGN) disclose?

Vistagen Therapeutics disclosed that directors Margaret FitzPatrick and Joanne Curley have decided not to stand for re-election at the 2026 Annual Meeting. Both will remain on the Board until their current terms end at that meeting.

When will the Vistagen Therapeutics directors step down from the board?

Both directors will step down at the 2026 Annual Meeting of Stockholders. They will continue to serve until the end of their current terms, providing continuity of governance through that meeting before their board service concludes.

Did the Vistagen Therapeutics directors resign immediately?

No, they did not resign immediately. Margaret FitzPatrick and Joanne Curley informed the company they will not seek re-election, but will continue as directors until the conclusion of the 2026 Annual Meeting of Stockholders, when their current terms expire.

Does this Vistagen update affect the VTGN stock listing?

The update does not change the company’s listing status. Vistagen’s common stock, with a par value of $0.001 per share, continues to trade on the Nasdaq Capital Market under the ticker symbol VTGN as indicated in the disclosure.

What meeting is referenced in the Vistagen board announcement?

The announcement references Vistagen Therapeutics’ 2026 Annual Meeting of Stockholders. At that meeting, directors Margaret FitzPatrick and Joanne Curley will complete their current board terms and will not stand for re-election to continue serving afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 05:13 PM EDT Learn about SEC filing dates

FALSE000141168500014116852024-09-232024-09-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 16, 2026

Vistagen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada			000-54014			20-5093315
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

343 Allerton Ave.

South San Francisco, California 94080

(Address of principal executive offices)

(650) 577-3600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			VTGN			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the “Company”), notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Each will continue to serve as a director until the end of her term at the 2026 Annual Meeting.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Vistagen Therapeutics, Inc.
Date: June 17, 2026			By:			/s/ Shawn K. Singh
						Shawn K. Singh President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB